Fosun Pharma Secures $60M Global Option for Phase III CNS Candidate AR1001 in Alzheimer’s Disease

On May 13, Fosun Pharma announced that its controlling subsidiary, Fosun Pharmaceutical Industry, and the South Korean biotechnology company AriBio jointly announced the signing of a global exclusive option agreement regarding the development, registration, manufacturing, and commercialization rights for AR1001, an innovative drug for Alzheimer’s disease, building on their prior collaboration.

This transaction adoptsUnder the “option fee + licensing fee” payment model, Fosun Pharma will pay AriBio an option fee of USD 60 million (approximately RMB 408 million) and shall have the right to decide whether to exercise the option within the agreed option period; upon exercising the option, Fosun Pharma will make upfront payments and regulatory milestone payments totaling up to USD 180 million;A sales milestone payment will be triggered when the annual sales of the licensed product reach at least $2.5 billion.

As agreed, AriBio shall provide all top-line data to Shanghai Fosun Pharmaceutical Development Co., Ltd. upon completion of the global multicenter Phase III clinical trials of the Licensed Product. Shanghai Fosun Pharmaceutical Development Co., Ltd. shall have the right to decide whether to exercise such exclusive option no later than 90 calendar days after the provision of such top-line data. If exercised, AriBio shall grant Shanghai Fosun Pharmaceutical Development Co., Ltd. the exclusive rights to develop, register, manufacture, and commercialize the Licensed Product in the Licensed Field (i.e., diagnosis, prevention, and treatment of all spectrums of Alzheimer’s disease) and within the Licensed Territory (including but not limited to global markets such as the United States, Europe, and Japan), and Shanghai Fosun Pharmaceutical Development Co., Ltd. shall serve as the Marketing Authorization Holder (MAH) for the Licensed Product in such territories.

This business development (BD) transaction marks the deepening and upgrading of the collaboration between Fosun Pharma and AriBio, which has spanned over a year. The partnership traces its origins to 2025, evolving from initial alignment in regional markets to comprehensive global synergy, driven by shared objectives and complementary resources in the field of neurodegenerative diseases.

On July 28 and December 31, 2025, Fosun Pharma Industry, a subsidiary controlled by Fosun Pharma, entered into License Agreement I and License Agreement II with AriBio and its downstream licensor, Newco, respectively. These agreements include the rights granted to Fosun Pharma Industry to develop, register, manufacture, and commercialize drugs containing the AR100 molecule as their active ingredient for the diagnosis, prevention, and treatment of Alzheimer’s disease and other neurological disorders in China and ten specified Southeast Asian countries.

AriBio, established in October 2010 and headquartered in South Korea, focuses on the field of neurodegenerative diseases. As of the date of Fosun Pharma’s announcement, in addition to advancing the global multicenter Phase III clinical trial of AR1001 for early Alzheimer’s disease, AriBio has two other investigational products that have entered Phase II clinical trials. Its pipeline is focused and precise, demonstrating strong R&D capabilities in the niche area of neurodegenerative diseases.

Financial data show that as of December 31, 2025, AriBio’s total assets amounted to approximately KRW 211.754 billion (equivalent to RMB 960 million), with shareholders’ equity of about KRW 61.051 billion. In 2025, the company generated revenue of KRW 10.976 billion and incurred a net loss of approximately KRW 31.229 billion, reflecting the typical profile of a company in an intensive R&D investment phase. This situation has become a key driver for its pursuit of external collaborations and capital infusion to accelerate pipeline development.

For Fosun Pharma,This collaboration marks a significant step in its expansion from regional to global markets. Previously, through two licensing agreements, Fosun had secured the rights to AR1001 in core Asia-Pacific regions. The signing of this exclusive option agreement means that Fosun is poised to extend the market coverage of this pipeline to major global pharmaceutical markets, including the United States, Europe, and Japan, thereby further enhancing its global footprint in the field of neurodegenerative diseases.

For AriBio,Fosun Pharma’s robust capabilities in clinical development, regulatory submission, manufacturing, and commercialization, coupled with ample financial resources, provide strong support for advancing the global Phase III clinical trials of AR1001, as well as its subsequent regulatory approval, market launch, and commercial implementation.

AR1001 is a small-molecule oral drug and a potential best-in-class therapy for the treatment of Alzheimer’s disease, featuring potent and highly selective inhibition of phosphodiesterase-5 (PDE-5).

Preclinical studies conducted to date have demonstrated that AR1001 effectively clears amyloid plaques associated with Alzheimer’s disease and inhibits abnormal phosphorylation of Tau protein—two core pathological mechanisms underlying the pathogenesis of Alzheimer’s disease. Additionally, it suppresses inflammatory responses in the central nervous system, providing neuroprotective effects. By exerting synergistic therapeutic effects through multiple targets, AR1001 holds promise for delaying disease progression in patients with Alzheimer’s disease from its root causes, rather than merely alleviating symptoms.

Controversially, the Phase II clinical trial of AR1001 failed to meet its prespecified primary efficacy endpoint: after 26 weeks of treatment, neither of the two core assessment scales for Alzheimer’s disease symptoms demonstrated statistically significant improvement.However, a benign improvement in Alzheimer’s disease-related plasma biomarkers was observed in the trial. This highly reference-worthy positive clinical signal not only supports AriBio’s continued advancement of AR1001 into the global Phase III clinical stage but also serves as a core consideration for Fosun Pharma’s optimism regarding the long-term value of its pipeline and its willingness to make substantial investments in this strategic layout.

Currently, the global multicenter Phase III clinical trial of AR1001 for the treatment of early Alzheimer’s disease (the POLARIS-AD study; NCT05531526) is ongoing. The trial has enrolled more than 1,500 patients across countries and regions including the United States, Europe, China, Canada, and South Korea, with enrollment completed in 2025. Top-line results are expected to be announced within 2026. Clinical trials conducted to date have demonstrated that AR1001 exhibits a favorable safety profile and blood-brain barrier penetrance, showing potential therapeutic efficacy in patients with early AD (ranging from mild cognitive impairment to mild dementia).

In recent years, Fosun Pharma has prioritized the central nervous system (CNS) disease sector, continuously enriching its pipeline matrix and optimizing its industrial layout through business development (BD) collaborations, equity acquisitions, and other strategic initiatives.

In addition to the AR1001 pipeline developed in collaboration with AriBio,In December 2025, Fosun Pharma Industry acquired a controlling stake in Green Valley Pharmaceutical by purchasing existing equity and subscribing to newly increased registered capital for approximately RMB 1.412 billion, thereby holding 51% of its equity.The core asset is sodium oligomannate capsules (brand name “Jiuqi Yi”), an Alzheimer’s drug mired in controversy yet holding potential value.

Including AR1001 and sodium oligomannate capsules, Fosun Pharma is actively exploring and building integrated diagnostic-therapeutic solutions with synergistic multi-technology pathways. The company has deployed non-invasive diagnostic and therapeutic equipment platforms, such as magnetoencephalography (MEG) systems and magnetic resonance-guided focused ultrasound (MRgFUS, or “magnetic wave knife”), establishing a “drug + device” collaborative innovation model for central nervous system (CNS) disorders. This strategy covers multiple subfields of neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease, forming a complete industrial chain layout from early-stage R&D and clinical development to commercialization.

From the perspective of industry development trends, the CNS field is ushering in unprecedented opportunities for growth, while still facing numerous challenges. With the intensifying global aging population, the prevalence of neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease continues to rise, creating a substantial gap in unmet clinical needs.

Consequently, collaboration in the central nervous system (CNS) field is becoming an industry norm. In recent years, numerous multinational pharmaceutical companies, including GSK, AbbVie, Takeda, Novartis, Roche, Sumitomo, and Merck & Co., have made high-profile strategic moves into the area of neurodegenerative diseases. The “pharmaceutical company + biotech” partnership model, exemplified by Fosun Pharma and AriBio, enables complementary resource allocation: biotech firms possess strong early-stage R&D capabilities, while established pharmaceutical companies offer comprehensive clinical development, regulatory affairs, and commercialization systems, along with ample financial support. This deep synergy can effectively reduce R&D risks and accelerate pipeline advancement.

Fosun Pharma’s continuous strategic alignment with this industry trend—through business development collaborations, equity acquisitions, and other means—aims to rapidly address pipeline gaps and enhance core competitiveness, positioning the company to secure a foothold in the fiercely competitive CNS landscape.